Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002313 · ClinicalTrials.gov registry record · Phase 1
A Study of Nystatin in HIV-Infected Patients
A Phase 1 study of HIV Infections, sponsored by Argus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00002313: Completed Phase 1 study of HIV Infections, sponsored by Argus Pharmaceuticals.
NCT00002313 is a Phase 1 study of HIV Infections that has completed, run by Argus Pharmaceuticals. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002313, a Phase 1 study of HIV Infections, has completed, sponsored by Argus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
To evaluate the clinical toxicity, safety, and potential anti-HIV activity of intravenous nystatin in patients with HIV infection who have completed protocol FDA 103C. To evaluate the safety and potential antiviral activity of intravenous nystatin and oral didanosine (ddI) administered in an alternating regimen in this patient population.
Conditions Studied
Interventions
- DRUG Nystatin
- DRUG Didanosine
Study Locations (1)
Texas
- Twelve Oaks Hosp - Houston
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002313
The ClinicalTrials.gov registry entry for NCT00002313 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Argus Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Nystatin is the first listed.
NCT00002313 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00002313 about?
NCT00002313 is a clinical study titled "A Study of Nystatin in HIV-Infected Patients". To evaluate the clinical toxicity, safety, and potential anti-HIV activity of intravenous nystatin in patients with HIV infection who have completed protocol FDA 103C. To evaluate the safety and potential antiviral activity of intravenous nystatin and oral didanosine (ddI) administered in an alterna...
What is the current status of trial NCT00002313?
This trial is currently completed. It is a Phase 1 study.
What conditions does trial NCT00002313 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002313?
The interventions under investigation include: Nystatin (DRUG), Didanosine (DRUG).
Who is sponsoring clinical trial NCT00002313?
This trial is sponsored by Argus Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002313 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.